There are several sets of guidelines for the treatment of infective endocarditis, reflecting the need for differing treatment in various countries and times. This review considers the need for differing treatment modalities and in particular the utility of the glycopeptide antibiotics vancomycin and teicoplanin. Specific recommendations are offered as to when to consider the use of glycopeptides, appropriate dosage, length of treatment course and whether to use monotherapy or combined therapy. Used judiciously, the glycopeptides give results as good as can be achieved with other antimicrobial agents without exceptional toxicity. The potential of teicoplanin for use in the outpatient treatment of infective endocarditis is considered
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Glycopeptide antibiotics, vancomycin and teicoplanin, inhibit cell wall synthesis in Gram-positive b...
There are several sets of guidelines for the treatment of infective endocarditis, reflecting the nee...
BACKGROUND: Despite the number of antibacterial agents currently available, endocarditis remains a d...
Glycopeptides have been recommended as therapy for endocarditis. MICs and MBCs of vancomycin and tei...
Infective endocarditis is an uncommon disease but retains a high mortality. Glycopeptides are used f...
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. V...
It would be difficult to envision the practice of infectious diseases over the past 20 years without...
The glycopeptide antibacterial drugs vancomycin and teicoplanin are widely used in hospitals for the...
Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usu...
Vancomycin and teicoplanin are the two glycopeptides currently used in the clinics for the treatment...
Infective endocarditis (IE), despite the diagnostic and therapeutic advances, still remains a seriou...
Seven cases of enterococcal endocarditis treated with teicoplanin (7-10 mg/kg/day for 28-105 days) a...
The present paper completes a series of papers on the current aspects of infective endocarditis (IE)...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Glycopeptide antibiotics, vancomycin and teicoplanin, inhibit cell wall synthesis in Gram-positive b...
There are several sets of guidelines for the treatment of infective endocarditis, reflecting the nee...
BACKGROUND: Despite the number of antibacterial agents currently available, endocarditis remains a d...
Glycopeptides have been recommended as therapy for endocarditis. MICs and MBCs of vancomycin and tei...
Infective endocarditis is an uncommon disease but retains a high mortality. Glycopeptides are used f...
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. V...
It would be difficult to envision the practice of infectious diseases over the past 20 years without...
The glycopeptide antibacterial drugs vancomycin and teicoplanin are widely used in hospitals for the...
Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usu...
Vancomycin and teicoplanin are the two glycopeptides currently used in the clinics for the treatment...
Infective endocarditis (IE), despite the diagnostic and therapeutic advances, still remains a seriou...
Seven cases of enterococcal endocarditis treated with teicoplanin (7-10 mg/kg/day for 28-105 days) a...
The present paper completes a series of papers on the current aspects of infective endocarditis (IE)...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Glycopeptide antibiotics, vancomycin and teicoplanin, inhibit cell wall synthesis in Gram-positive b...